Fumiaki Nakamura

Dr. Fumiaki Nakamura

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2019 in Marine Drugs
Verified
Journal Article
Open access
PDF file
AMAlejandro M. Mayer
Alejandro M. Mayer
AGAimee J. Guerrero
Aimee J. Guerrero
ARAbimael D. D. Rodriguez
Abimael D. D. Rodriguez
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
FNFumiaki Nakamura
Fumiaki Nakamura
NFNobuhiro Fusetani
Nobuhiro Fusetani
The systematic review of the marine pharmacology literature from 2014 to 2015 was completed in a manner consistent with the 1998–2013 reviews of this series. Research in marine pharmacology during 2014–2015, which was reported by investigators in 43 countries, described novel findings on the preclinical pharmacology of 301 marine compounds. These observations included antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral, and anthelmintic pharmacological activities for 133 marine natural products, 85 marine compounds with antidiabetic, and anti-inflammatory activities, as well as those that affected the immune and nervous system, and 83 marine compounds that displayed miscellaneous mechanisms of action, and may probably contribute to novel pharmacological classes upon further research. Thus, in 2014–2015, the preclinical marine natural product pharmacology pipeline provided novel pharmacology as well as new lead compounds for the clinical marine pharmaceutical pipeline, and thus continued to contribute to ongoing global research for alternative therapeutic approaches to many disease categories.

21 January 2021 in Marine Drugs
Verified
Journal Article
Open access
PDF file
AMAlejandro M. Mayer
Alejandro M. Mayer
AGAimee J. Guerrero
Aimee J. Guerrero
ARAbimael D. D. Rodriguez
Abimael D. D. Rodriguez
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
FNFumiaki Nakamura
Fumiaki Nakamura
NFNobuhiro Fusetani
Nobuhiro Fusetani
The review of the 2016–2017 marine pharmacology literature was prepared in a manner similar as the 10 prior reviews of this series. Preclinical marine pharmacology research during 2016–2017 assessed 313 marine compounds with novel pharmacology reported by a growing number of investigators from 54 countries. The peer-reviewed literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral activities for 123 marine natural products, 111 marine compounds with antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while in contrast 79 marine compounds displayed miscellaneous mechanisms of action which upon further investigation may contribute to several pharmacological classes. Therefore, in 2016–2017, the preclinical marine natural product pharmacology pipeline generated both novel pharmacology as well as potentially new lead compounds for the growing clinical marine pharmaceutical pipeline, and thus sustained with its contributions the global research for novel and effective therapeutic strategies for multiple disease categories.

30 June 2024 in Marine Drugs
Verified
Journal Article
Open access
PDF file
AMAlejandro M. Mayer
Alejandro M. Mayer
VMVeronica A. Mayer
Veronica A. Mayer
MSMichelle Swanson-Mungerson
Michelle Swanson-Mungerson
Marsha PierceMarsha Pierce
Marsha Pierce
ARAbimael D. D. Rodriguez
Abimael D. D. Rodriguez
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
The current 2019–2021 marine pharmacology literature review provides a continuation of previous reviews covering the period 1998 to 2018. Preclinical marine pharmacology research during 2019–2021 was published by researchers in 42 countries and contributed novel mechanism-of-action pharmacology for 171 structurally characterized marine compounds. The peer-reviewed marine natural product pharmacology literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral mechanism-of-action studies for 49 compounds, 87 compounds with antidiabetic and anti-inflammatory activities that also affected the immune and nervous system, while another group of 51 compounds demonstrated novel miscellaneous mechanisms of action, which upon further investigation, may contribute to several pharmacological classes. Thus, in 2019–2021, a very active preclinical marine natural product pharmacology pipeline provided novel mechanisms of action as well as new lead chemistry for the clinical marine pharmaceutical pipeline targeting the therapy of several disease categories.

6 August 2022 in Pharmacological Research
Verified
Journal Article
Open access
AMAlejandro M. Mayer
Alejandro M. Mayer
Marsha PierceMarsha Pierce
Marsha Pierce
KHKatelyn Howe
Katelyn Howe
ARAbimael D. D. Rodriguez
Abimael D. D. Rodriguez
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
NFNobuhiro Fusetani
Nobuhiro Fusetani
The 2018 marine pharmacology literature review represents a continuation of the previous 11 reviews of a series initiated in 1998. Preclinical marine pharmacology research during 2018 was performed by investigators in 44 countries and contributed novel pharmacology for 195 marine compounds. The peer-reviewed marine natural products pharmacology literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral activities for 53 compounds, 73 compounds which presented antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while in contrast 69 compounds were reported to show miscellaneous mechanisms of action which may contribute upon further investigation to several pharmacological classes. Thus, in 2018, the preclinical marine natural product pharmacology pipeline continued to report novel pharmacology as well as new lead compounds for the clinical marine pharmaceutical pipeline, which currently contributes to therapeutic strategies for several disease categories.

16 September 2014 in Journal of the American Heart Association
Verified
Journal Article
Open access
SKSatoru Kamitani
Satoru Kamitani
KNKunihiro Nishimura
Kunihiro Nishimura
FNFumiaki Nakamura
Fumiaki Nakamura
AKAkiko Kada
Akiko Kada
JNJyoji Nakagawara
Jyoji Nakagawara
KIKoji Iihara
Koji Iihara
Background: Poor outcomes have been reported for stroke patients admitted outside of regular working hours. However, few studies have adjusted for case severity. In this nationwide assessment, we examined relationships between hospital admission time and disabilities at discharge while considering case severity. Methods and Results: We analyzed 35 685 acute stroke patients admitted to 262 hospitals between April 2010 and May 2011 for ischemic stroke (IS), intracerebral hemorrhage (ICH), or subarachnoid hemorrhage (SAH). The proportion of disabilities/death at discharge as measured by the modified Rankin Scale ( mRS ) was quantified. We constructed 2 hierarchical logistic regression models to estimate the effect of admission time, one adjusted for age, sex, comorbidities, and number of beds; and the second adjusted for the effect of consciousness levels and the above variables at admission. The percentage of severe disabilities/death at discharge increased for patients admitted outside of regular hours (22.8%, 27.2%, and 28.2% for working‐hour, off‐hour, and nighttime; P <0.001). These tendencies were significant in the bivariate and multivariable models without adjusting for consciousness level. However, the effects of off‐hour or nighttime admissions were negated when adjusted for consciousness levels at admission (adjusted OR, 1.00 and 0.99; 95% CI, 1.00 to 1.13 and 0.89 to 1.10; P =0.067 and 0.851 for off‐hour and nighttime, respectively, versus working‐hour). The same trend was observed when each stroke subtype was stratified. Conclusions: The well‐known off‐hour effect might be attributed to the severely ill patient population. Thus, sustained stroke care that is sufficient to treat severely ill patients during off‐hours is important.

1 January 2016 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Open access
MZMasayoshi Zaitsu
Masayoshi Zaitsu
FNFumiaki Nakamura
Fumiaki Nakamura
STSatoshi Toyokawa
Satoshi Toyokawa
ATAkiko Tonooka
Akiko Tonooka
TTTakumi Takeuchi
Takumi Takeuchi
YKYasuki Kobayashi
Yasuki Kobayashi
Bladder cancer is common in Western countries, but not in Japan. Established risk factors are smoking and high-risk jobs such as printing and manufacturing. The risk of alcohol consumption in bladder cancer has been the recent focus; however, available literature on alcohol consumption and bladder cancer has been limited from Japanese population, thought to have a weak genetic tolerance to acetaldehyde. We aimed to determine whether alcohol consumption is an independent risk factor for bladder cancer among Japanese. The study was a matched case-control study from the nationwide Japanese clinical database administered by the Rosai Hospital group. We identified 739 cases of bladder cancer diagnosed between 2005 (when the database was established) and 2014 and 7,196 controls matched by sex, age, hospital, and admission period. We estimated the odds ratio of alcohol consumption for bladder cancer adjusted for the amount of smoking, high-risk occupations, and comorbidities (hypertension, hyperlipidemia, diabetes, hyperuricemia, and obesity) with conditional logistic regression. The risk of bladder cancer was significantly higher in ever drinkers than in never drinkers (odds ratio, 1.33; 95% confidence interval, 1.06 to 1.66). Furthermore, the risk threshold for alcohol consumption was more than 15 g of alcohol intake per day (one, 180-mL cup equivalent to 6 ounces of Japanese sake containing 23 grams of alcohol). Among Japanese, alcohol consumption may be an independent risk factor for bladder cancer, with a lower risk threshold.